Tumor necrosis factor-alpha antibody for induction of remission in Crohn's disease

Cochrane Database of Systematic Reviews

Volumn , Issue 4, 2009, Pages

  Akobeng, Anthony K ^a   Zachos, Mary ^b  

^a ROYAL MANCHESTER CHILDREN S HOSPITAL   (United Kingdom)

^b HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

Antibodies, monoclonal *therapeutic use ; Crohn disease *drug therapy ; Gastrointestinal agents therapeutic use ; Humans; Immunoglobulin G therapeutic use ; Immunology ; Randomized controlled trials as topic; Receptors, tumor necrosis factor therapeutic use ; Remission induction; Tumor necrosis factor alpha *antagonists inhibitors

Indexed keywords

AZATHIOPRINE; BUDESONIDE; ETANERCEPT; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; PLACEBO; PREDNISOLONE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORTICOSTEROID THERAPY; CROHN DISEASE; DISEASE ACTIVITY; DRUG EFFICACY; DRUG SAFETY; EFFECT SIZE; FOLLOW UP; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; REMISSION; REVIEW; STATISTICAL ANALYSIS;

EID: 77950150465     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD003574.pub2     Document Type: Review

References (27)

1. Sandborn 2001a {published data only} Sandborn WJ, Feagan BG, Hanauer SB, Present DH, Sutherland LR, Kamm M, et al.An engineered human antibody to TNF (CDP571) for active Crohn's disease: A randomized double-blind placebo-controlled trial. Gastroenterology 2001;120:1330-8.
2. Sandborn 2001b {published data only} Sandborn WJ, Hanauer SB, Katz S, Safdi M, Wolf DG, Baerg RD, et al.Etanercept for active Crohn's disease: A randomized double-blind, placebo-controlled trial. Gastroenterology 2001;121: 1088-94.
3. Stack 1997 {published data only} Stack WA, Mann SD, Roy AJ, Heath P, Sopwith M, Freeman J, et al.Randomised controlled trial of CDP571 antibody to tumour necrosis factor-alpha in Crohn's disease. Lancet 1997;349:521-4.
4. Targan 1997 {published data only} Targan SR, Hanauer SB, van Deventer SJH, Mayer L, Present DH, Braakman T, et al.A short term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. N Engl J Med 1997;337:1029-35.
5. Baldassano 2003 {published data only} Baldassano R, Braegger CP, Escher JC, De Woody K, Hendricks DF, Keenan G, et al.Infliximab (REMICADE) therapy in the treatment of pediatric Crohn's disease. Am J Gastroenterol 2003;98:833-8.
6. D'Haens 1999 {published data only} D'Haens G, van Deventer S, van Hogezand R, Chalmers D, Kothe C, Baert F, et al.Endoscopic and histologic healing with infliximab anti-tumor Necrosis factor antibodies in Crohn's Disease: a European multicentre trial. Gastroenterology 1999;116:1029-34.
7. Hanauer 2002 {published data only} Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, et al.Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002;359:1541-9.
8. Present 1999 {published data only} Present DH, Rutgeerts P, Targan S, Hanauer SB, Mayer L, van Hogezand RA, et al.Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999;340:1398-405.
9. Rutgeerts 1999 {published data only} Rutgeerts P, D'Haens G, Targan S, Vasiliauskas E, Hanauer SB, Present DH, et al.Efficacy and safety of retreatment with antitumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology 1999;117:761-9.
10. Rutgeerts 2003 {published data only} Rutgeerts P, Lemmens L, Van Assche G, Noman M, Borghini-Fuhrer I, Goedkoop R. Treatment of active Crohn's disease with onercept (recombinant human soluble p55 tumour necrosis factor receptor): results of a randomized, open label study. Aliment Pharmacol Ther 2003;17:185-92.
11. Baert 1999 Baert FJ, D'Haens GR, Peeters M, Hiele MI, Schaible TF, Shealy D, et al.Tumor necrosis factor alpha antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitis. Gastroenterology 1999;116:22-8.
12. Bauditz 1997 Bauditz J, Haemling J, Ortner M, Lochs H, Raedler A, Schreiber S. Treatment with tumour necrosis factor inhibitor oxpentifylline does not improve corticosteroid dependent chronic active Crohn's disease. Gut 1997;40:470-4.
13. Bell 2000 Bell SJ, Kamm MA. Review article: the clinical role of anti-TNF alpha antibody treatment in Crohn's disease. Aliment Pharmacol Ther 2000;14:501-14.
14. Breese 1994 Breese EJ, Michie CA, Nicholls SW, Murch SH, Williams CB, Domizio P, et al.Tumor necrosis factor -alpha producing cells in the intestinal musosa of children with inflammatory bowel disease. Gastroenterology 1994;106:1455-66.
15. Brown 2002 Brown SL, Greene MH, Gershon SK, Edwards ET, Braun MM. Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration. Arthritis Rheum 2002;46:3151-8.
16. Clarke 2001 Clarke M, Oxman AD, editors. Cochrane Reviewers' Handbook 4.1.4 [updated October 2001]. In: The Cochrane Library, Issue 4, 2001. Oxford : Update software. Updated quarterly.
17. Jadad 1996 Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJM, Gavaghan DJ, et al.Assessing the quality of reports of randomized clinical trials: Is blinding necessary?. Control Clin Trials 1996;17: 1-12.
18. Keane 2001 Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, et al.Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001; 345:1098-104.
19. MacDonald 1990 MacDonald TT, Hutchings P, Choy MY, Murch S, Cooke A. Tumour necrosis factor-alpha and interferon gamma production measured at the single cell level in normal and inflamed human intestine. Clin Exp Immunol 1990;81:301-5.
20. Murch 1991 Murch SH, Lamkin VA, Savage MO, Walker Smith JA, MacDonald TT. Serum concentrations of tumour necrosis factor-alpha in childhood chronic inflammatory bowel disease. Gut 1991; 32:913-7.
21. Papadikas 2000 Papadikas KA, Targan SR. Tumor necrosis factor: Biology and therapeutic inhibitors. Gastroenterolgy 2000;119:1148- 57.
22. Pitkin 1999 Pitkin RM, Branagan MA, Burmeister LF. Accuracy of data in abstracts of published research articles. JAMA 1999;281:1110-1.
23. Rampton 1999 Rampton DS. Management of Crohn's disease. BMJ 1999;319: 1480-5.
24. Reimund 1996 Reimund JM, Wittersheim C, Dumont S, Muller CD, Kenney JS, Baumann R, et al.Increased production of tumour necrosis factor-a, interleukin 1b, and interleukin-6 by morphologically normal intestinal biopsies from patients with Crohn's disease. Gut 1996;39: 684-9.
25. Scallon 1995 Scallon BJ, Moore MA, Trinh H, Knight DM, Ghrayeb J. Chimeric anti TNF-alpha monoclonal antibody Ca2 binds recombinant trasmembrane TNF- alpha and activates immune effector functions. Cytokine 1995;7:251-9.
26. Shanahan 2001 Shanahan F. Inflammatory bowel disease: immunodiagnostics, immunotherapeutics and ecotherapeutics. Gastroenterology 2001; 120:622-35.
27. Siegel 1995 Siegel SA, Shealy DJ, Nakada MT, Le J, Woulfe DS, Probert L, et al.The mouse/human chimeric monoclonal antibody cA2 neutralizes in vitro and protects transgenic mice from cachexia and TNF- lethality in vivo. Cytokine 1995;7:15-25.